Advancing Prognostic Models in Diffuse Large B-Cell Lymphoma Treatment

Jelena Jelicic presented a study at the ASH meeting in San Diego on prognostic models for diffuse large B-cell lymphoma in patients under 70. The study aimed to evaluate the utility of different prognostic models, specifically comparing the traditional International Prognostic Index (IPI) with the more recent NCCN-IPI. The findings suggest that NCCN-IPI better discriminates between risk categories and could potentially include more patients in clinical trials.